• Publications
  • Influence
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
TLDR
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
TLDR
Results underline the need of genetic screening for all susceptibility factors as part of clinical management of aHUS and for identification of patients who could safely benefit from kidney transplant.
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases.
TLDR
Interventions targeting CKD, particularly to reduce urine protein excretion, are efficacious, cost-effective methods of improving cardiovascular and renal outcomes, especially when applied to high-risk groups and Integration of these approaches within NCD programs could minimize the need for renal replacement therapy.
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
TLDR
Nonfamilial thrombotic throm bocytopenic purpura is due to an inhibitor of von Willebrand factor-cleaving protease, whereas the familial form seems to be caused by a constitutional deficiency of the protease.
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
TLDR
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke.
Atypical hemolytic-uremic syndrome.
TLDR
Current concepts about the pathobiology of atypical hemolytic–uremic syndrome are reviewed and its diagnosis and management are reviewed.
...
...